Evidence method
Level · gp.fundamentals.capex_revenue_ratio
4.71% · OPTIONAL · NOT_ENOUGH_HISTORY
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
INVE · Mar 31, 2023
Identiv, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0000950170-23-019845General Corporate
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
-18.07% · OPTIONAL · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.inventory_revenue_ratio
117.74% · OPTIONAL · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.gross_margin
35.43% · CORE · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.operating_margin
-10.51% · CORE · NOT_ENOUGH_HISTORY
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
10.41% · OPTIONAL · NOT_ENOUGH_HISTORY
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History14 statesHistory building
Mar 31, 20230/6 normalizedLevel 3Jun 30, 20230/6 normalizedLevel 3Sep 30, 20230/6 normalizedLevel 3Dec 31, 20230/6 normalizedLevel 3Mar 31, 20240/7 normalizedLevel 3Jun 30, 20240/7 normalizedLevel 3Sep 30, 20240/8 normalizedLevel 3Dec 31, 20240/8 normalizedLevel 3Mar 31, 20256/8 normalizedLevel 3Jun 30, 20256/8 normalizedLevel 3Sep 30, 20256/8 normalizedLevel 3Dec 31, 20256/8 normalizedLevel 3Mar 31, 20267/8 normalizedLevel 3Jun 30, 20267/8 normalizedLevel 3
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.